Illustration of an eye affected by ocular rosacea, highlighting redness and inflammation. Represents the condition and the need for treatment.

Tear Trouble? How Antibiotics Could Be Your Secret Weapon Against Ocular Rosacea

Beau Callahan monogram
Beau Callahan in Health & Wellness October 2026 • 4 min read.

"New research shows promise for those battling ocular rosacea, offering a potential path to clearer vision and relief from this frustrating condition."


If you're battling the persistent discomfort of ocular rosacea—that gritty, red-eyed feeling—you're not alone. This condition, affecting the eyes and eyelids, can significantly impact your quality of life. But what if a common solution held the key to relief? Recent research is shining a light on how antibiotics, already familiar in treating other infections, could be a game-changer in managing ocular rosacea.

This exploration delves into a study that investigated the use of antibiotics azithromycin and doxycycline. The research focuses on the concentration of specific substances in tear fluid, offering insights into how these medications might alleviate the symptoms. Let's uncover the findings and what they mean for those seeking brighter days.

Before we dive in, it's important to clarify that this article is for informational purposes and should not be taken as medical advice. Always consult with your eye doctor or healthcare provider for personalized guidance and treatment options. Now, let's explore the promising world of antibiotics and ocular rosacea.

AI Search Multiple angles on this topic

Prevalence and Clinical Impact

Ocular rosacea commonly presents with dry eye, a foreign-body sensation, and photophobia. Reported prevalence varies substantially: a 2025 systematic review found estimates among people with cutaneous rosacea ranging from 0.03% to 65%, while another review reported ocular manifestations in 6% to 72% of people with rosacea. A 2025 review also reported that 58.0% of patients with rosacea may have ocular rosacea, underscoring the condition's potentially significant burden while highlighting uncertainty in measurement.

Stepwise Management

Commonly described treatment options include eyelid hygiene, artificial tears, topical or oral antibiotics, cyclosporine ophthalmic emulsion, oral vitamin A derivatives, and intense pulsed light. Guidance summarized by DrOracle recommends beginning with eyelid hygiene and artificial tears, then considering oral doxycycline when basic measures do not control symptoms, with ophthalmology referral for moderate-to-severe disease. However, a 2024 systematic review noted that direct comparisons between ocular rosacea treatments are lacking, limiting confidence about which option is best for individual patients.

From Recognition to Management

Rosacea was first medically described by Dr. Guy de Chauliac, a French surgeon, in the 14th century. Ocular rosacea became recognized as an eye-related manifestation in which patients may experience gritty or bloodshot eyes, along with redness, burning, itching, or watering. Modern clinical guidance emphasizes that the condition has no cure, but treatment can control symptoms and help prevent vision-threatening complications.

Unpacking Ocular Rosacea: What's Happening in Your Eyes?

Illustration of an eye affected by ocular rosacea, highlighting redness and inflammation. Represents the condition and the need for treatment.

Ocular rosacea is more than just dry or irritated eyes; it's a chronic inflammatory condition affecting the eyes and the surrounding areas. The core issue involves a complex interplay of factors, including the immune system, blood vessels, and nerves. This leads to inflammation that causes various uncomfortable symptoms. The effects range from redness and a gritty sensation to blurred vision and light sensitivity. The condition can affect the eyelids, causing them to become inflamed and crusted. If left untreated, ocular rosacea can even affect the cornea, potentially leading to vision problems.

In the tear film, which is the eye's natural protective layer, certain substances play a crucial role. Specifically, interleukin-1 alpha (IL-1a) and matrix metalloproteinase-9 (MMP-9) are two key players in this condition. These substances are involved in the inflammatory process and can contribute to the damage observed in ocular rosacea.

  • IL-1a: A pro-inflammatory cytokine that promotes inflammation.
  • MMP-9: An enzyme that breaks down tissues, contributing to eye damage.
AI Search Multiple angles on this topic

New Directions in Research

Recent reviews describe ocular rosacea as a chronic inflammatory disorder affecting the ocular surface and often associated with cutaneous rosacea. Current research examines pathophysiology, clinical features, treatment strategies, and management in both adults and children. Emerging areas include immune dysregulation, microbiome alterations, and potential therapeutic targets.

Limits and Uncertainty

Antibiotics may be useful for some people with ocular rosacea, but they are not a guaranteed solution. Symptoms and treatment responses can vary, and persistent or worsening eye problems may require specialist assessment. Because ocular rosacea is chronic and has no established cure, management may focus on controlling symptoms and reducing complications rather than eliminating the condition.

Balancing Treatment Options

Ocular rosacea can affect ocular health, appearance, and comfort, making treatment selection an individualized decision. Available approaches may include local measures and medical therapies, depending on the patient's symptoms and clinical findings. Optimizing care therefore requires familiarity with the condition and its range of treatment options.

Understanding these components helps explain the purpose of the study. Researchers sought to determine how antibiotics might influence the levels of IL-1a and MMP-9 in the tear fluid, potentially offering a way to reduce inflammation and alleviate symptoms.

A Brighter Outlook for Ocular Rosacea

The findings of this research offer a glimmer of hope for those struggling with ocular rosacea. While more research is needed, the potential of antibiotics like azithromycin and doxycycline to manage this condition is an exciting development. If you are experiencing symptoms of ocular rosacea, consult your eye doctor or healthcare provider for diagnosis and treatment options, which could include antibiotics and other therapies. With the right approach, you can take steps towards clearer vision and improved eye health.

AI Search Multiple angles on this topic

Cyclosporine and Doxycycline Compared

A comparative study evaluated topical cyclosporine A emulsion and oral doxycycline for rosacea-associated ocular changes and dry-eye complaints. The study screened 110 patients with rosacea, of whom 38 had the relevant ocular findings described in the report. Its design directly addressed how these two treatments performed against each other, offering comparative evidence rather than relying only on separate treatment studies.

What Research May Clarify

Future research may help determine which patients benefit most from antibiotics and how they should be combined with other treatments. More direct comparisons and longer-term studies could clarify effectiveness, tolerability, and durability of response. Research into inflammation, immune regulation, and the ocular microbiome may also produce new treatment targets.

Diagnosis Across Systems

Rosacea management may involve monotherapies or multimodal combinations spanning topical, systemic, laser and light, alternative, and combination therapies. Diagnosing ocular rosacea is challenging because its clinical presentation is heterogeneous. Chronic blepharitis and meibomian gland dysfunction are common findings, and ocular involvement may appear before skin symptoms, complicating recognition.

Living With Ocular Rosacea

Ocular rosacea can affect comfort, appearance, and day-to-day visual experience. Burning, watering, redness, itching, or a gritty sensation may be disruptive even when the condition is not immediately vision-threatening. Because symptoms and severity can differ, real-world care may require ongoing adjustment and attention to both symptom control and eye health.

Reported responses across treatments and small studies

  • 91%; 89%A systematic review reported complete or partial responses in 91% of patients receiving topical antimicrobials (82 of 90) and 89% receiving oral antibiotics (525 of 580).[1]
  • 80%In a 15-patient report, slow-release doxycycline at 40 mg once daily was associated with a marked decrease in ocular complaints in 80% of patients.[2]

What the response figures can and cannot tell us

The review’s response percentages suggest that several approaches have been associated with improvement, but they do not establish that one is best: the underlying evidence does not directly compare treatments.[1]

Doxycycline has reported effects on inflammatory cells and processes involved in tissue breakdown, which offers a possible explanation for its use alongside topical therapies; this does not by itself establish how much those effects improve eye symptoms.[2]

How the reported treatment results differ in scope

The guideline notes that there are no randomized controlled trials establishing the best compounds or optimal treatment duration for ocular rosacea, adding an important limit to comparisons between reported results.[3]

What stronger comparisons would need to resolve

  • What treatment duration and compounds would perform best in randomized trials, given that the guideline reports no such trials on these questions?[3]

Terms used in treatment reports

Cyclosporine A
An agent described in the cited report as having anti-inflammatory effects.[2]

Sources

  1. Treatment of ocular rosacea: a systematic review. (onlinelibrary.wiley.com)
  2. Clinical Findings, Follow-up and Treatment Results in Patients with Ocular Rosacea (pmc.ncbi.nlm.nih.gov)
  3. S2k guideline: Rosacea (epub.ub.uni-muenchen.de)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly is ocular rosacea, and how does it differ from just having dry eyes?

Ocular rosacea is a chronic inflammatory condition affecting the eyes and surrounding areas, involving the immune system, blood vessels, and nerves. Unlike simple dry eyes, it involves inflammation that causes symptoms like redness, a gritty sensation, blurred vision, and light sensitivity. It can also affect the eyelids, potentially leading to vision problems if untreated. Key substances like interleukin-1 alpha (IL-1a) and matrix metalloproteinase-9 (MMP-9) contribute to the inflammatory process and tissue damage, differentiating it from common dryness.

2

How might antibiotics like azithromycin and doxycycline help with ocular rosacea?

Research suggests that antibiotics like azithromycin and doxycycline may help manage ocular rosacea by influencing the levels of specific substances in tear fluid. The study investigated the concentration of interleukin-1 alpha (IL-1a) and matrix metalloproteinase-9 (MMP-9) in tear fluid to determine how these medications might alleviate the symptoms. The goal is that by reducing the levels of IL-1a (a pro-inflammatory cytokine) and MMP-9 (an enzyme that breaks down tissues), inflammation could be reduced, thus alleviating the symptoms of ocular rosacea.

3

What are interleukin-1 alpha (IL-1a) and matrix metalloproteinase-9 (MMP-9), and what roles do they play in ocular rosacea?

Interleukin-1 alpha (IL-1a) is a pro-inflammatory cytokine that promotes inflammation within the eye and surrounding tissues. Matrix metalloproteinase-9 (MMP-9) is an enzyme that breaks down tissues, contributing to eye damage. In ocular rosacea, both IL-1a and MMP-9 are key players in the inflammatory process and contribute to the damage observed. Reducing the levels of these substances may help to reduce the inflammation and tissue damage associated with this condition.

4

If antibiotics like azithromycin and doxycycline show promise for ocular rosacea, are there potential long-term implications of using them for this condition, considering antibiotic resistance?

While azithromycin and doxycycline show promise in managing ocular rosacea by targeting interleukin-1 alpha (IL-1a) and matrix metalloproteinase-9 (MMP-9), the long-term implications, particularly concerning antibiotic resistance, are important to consider. Prolonged use of antibiotics can lead to bacteria developing resistance, making the antibiotics less effective against bacterial infections. In the context of ocular rosacea, where the condition is primarily inflammatory rather than directly caused by bacterial infection, long-term antibiotic use should be carefully evaluated. Future research is necessary to determine the optimal duration and dosage of antibiotics, balancing the benefits of symptom relief with the risks of promoting antibiotic resistance. Alternative therapies that target IL-1a and MMP-9 without the use of antibiotics may also be explored to minimize these risks.

5

Beyond antibiotics, what other treatment options or approaches are available or being explored for managing ocular rosacea and its associated inflammation driven by substances like interleukin-1 alpha (IL-1a) and matrix metalloproteinase-9 (MMP-9)?

Beyond antibiotics like azithromycin and doxycycline, several other treatment options and approaches are available or being explored for managing ocular rosacea. These often aim to reduce inflammation and alleviate symptoms without relying solely on antibiotics. Some common treatments include artificial tears to lubricate the eyes, warm compresses to soothe inflammation, and eyelid hygiene practices to reduce bacteria and debris. Topical treatments, such as corticosteroids or calcineurin inhibitors, may also be prescribed to target inflammation directly. Emerging therapies include the use of intense pulsed light (IPL) therapy to reduce inflammation and improve meibomian gland function. Additionally, research is ongoing to develop targeted therapies that specifically inhibit interleukin-1 alpha (IL-1a) and matrix metalloproteinase-9 (MMP-9), potentially offering more precise and effective treatments with fewer side effects.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.